GlassScriptPhysician profile
Matthew N Powell
NPI 1154316222
$10,551.63
in general payments reported to CMS, 2019-2025
50 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $1,209 · 2021: $1,583 · 2022: $1,329 · 2023: $1,673 · 2024: $2,185 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,839.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,748.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,474.21 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,042.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $805.73 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $760.59 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Pfizer INC. | $702.23 | 2019-2025 | |
| Lilly USA, LLC | $634.91 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $499.72 | 2019-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $214.77 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.44 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $192.28 | 2023-2024 | Voquezna |
| Stryker Corporation | $175.00 | 2025 | Pangea |
| Horizon Therapeutics Plc | $167.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $153.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.21 | 2020-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.